African Swine Fever - available

Control ToolsDisease details
Sources of informationRisks
ConclusionScore criteria
Prioritisation ModelGap Analysis

Control Tools

Diagnostics availability

Commercial diagnostic kits available worldwide

Available mainly from Spanish Company . ELISA INGEZIM K3.

Commercial diagnostic kits available in Europe

Available mainly from Spanish Company. ELISA INGEZIM K3.
In house: OIE- ELISA and Immunoblotting from CRL for ASF.

Diagnostic kits validated by International, European or National Standards

By Community Reference Laboratory for ASF:

  • ELISA INGEZIM K3.
  • in house: OIE –ELISA, Immunoblotting test, PCR conventional and Real-Time PCR.

Diagnostic method(s) described by International, European or National standards

Identification of the agent:

  • Isolation: Cell culture inoculation (primary cultures of pig monocytes or bone marrow cells - most isolates produce haemadsorption).
  • Pig inoculation - unvaccinated and vaccinated against classical swine fever (hog cholera).
  • Antigen detection by direct immuno-fluorescence.
  • Detection of virus genome by polymerase chain reaction (PCR).

Serological tests:

  • ELISA
  • Indirect fluorescent antibody test
  • Immunoblotting (confirmatory test)
  • Counter immunoelectrophoresis test (only for screening of large groups)

Commercial potential for diagnostic kits in Europe

Moderate potential to date, going increasing due to the current situation.

DIVA tests required and/or available

None available but would be required of vaccines were available.

GAP: no DIVA test

Opportunities for new developments

Current methods are relatively rapid diagnostic tests but require centralized laboratory facilities and clinical specimen submissions which delays disease diagnosis. Pen side tests could improve the speed of diagnosis, Improved capacity for detection and control of African swine fever in East Africa and West Africa through supply of ELISA kits and PCR primers and training in their use. Application of sero-diagnostic tests and detection of asymptomatic carrier animals using sensitive DNA-based tests to provide improved surveillance and pathogen characterisation in regions where outbreaks have occurred.

Vaccines availability

Commercial vaccines availability (globally)

None.

Commercial vaccines authorised in Europe

None.

Marker vaccines available worldwide

None.

Marker vaccines authorised in Europe

None.

Effectiveness of vaccines / Main shortcomings of current vaccines

No vaccines available.

Commercial potential for vaccines in Europe

Limited, as only found in Sardinia. Higher potential in Africa.

Regulatory and/or policy challenges to approval

Needs for authorisation in country to be used in.

Commercial feasibility (e.g manufacturing)

Until vaccines developed difficult to assess.

Opportunity for barrier protection

Not at present.

Opportunity for new developments

Attempts over many years to develop inactivated or attenuated vaccines to ASF have failed. Inactivated vaccines have conferred no protection. Attempts to attenuate the virus through passage in cell culture have not been successful, - DNA vaccine strategies have not been successful to date. - Deletion mutants strategies have not been successful to date.

GAPS:

  • Knowledge/molecular basis and understanding immune mechanisms of surviving pigs to resist a challenge with the homologous virus.
  • Knowledge of inhibition mechanisms for virus replication. New developments based on ne , non conventional, strategies.
  • Characterization of the mechanisms/Identification of genes related to virulence of the isolates.

Pharmaceutical availability

Current therapy (curative and preventive)

None.

Future therapy

Some studies are on going. Preliminary results obtained by “in-vitro” experiments using antiviral substances that antivirals might be used as an additional tool in ASF control.

GAP: Lack of knowledge on antivirals therapy for ASF.

Commercial potential for pharmaceuticals in Europe

None at present.

Regulatory and/or policy challenges to approval

Not applicable.

Commercial feasibility (e.g manufacturing)

Low.

Opportunities for new developments

None.

New developments for diagnostic tests

Requirements for diagnostics development

Kinetics of antibody response.

Understanding of viral replication at genome and protein level.

  • Serological techniques: The EU project ASFRISK is performing a very deep study about the real needs for further requirements of new diagnostic developments. Results indicate that for antibody detection techniques already exist several good antigenic recombinant candidates exhibit very good sensitivity and specificity. The best one have been evaluated and in house validated for new serological ELISA test, now under evaluation for a commercial prototype.
  • Virus detection techniques: New PCR and nucleic acid detection methods using different strategies have been developed under ASFRISK, that now are under evaluation.

Currently there are very good tools in terms of sensitivity and specificity for ASF diagnosis, however very few commercial kits (serological , PCR) available.

  • Penside test are on going for antibody and viral detection. However they are not ready at present date.
  • Several Real time PCR tests have been developed standardised and optimised for several Laboratories with very promising results, showing a very good sensitivity and specificity (studies under EPIZONE ring trial evaluation). . However not validated to date.

GAPS:

  • Validation of the recently optimized confirmatory serological test, and nucleic acid and PCR tests developed within ASFRISK and others evaluated under EPIZONE.
  • Maintain working to obtain validated diagnostic tools, which could be easily upgraded to a high throughput application.
  • In vivo experiments with circulating eastern Africa isolates confirms the sensitivity of Serological (OIE ELISA, Ingenasa ELISA and RP-ELISA prototypes and virus detection techniques using 4 out of 22 ASFV different genotypes . However, the studies should be extended using other relevant ASFV genotypes.
  • On-site first-line tools - Penside test and front line diagnostic tests - useful for a very rapid application in case of sanitary emergency.
  • Lack of confirmatory serological test commercially available.
  • Available commercial kits are yet scarce.
  • Few commercial interest for licensing.

Time to develop new or improved diagnostics

2-5 years. As a result of ASFRISK several new or improved techniques are coming soon as in house methods. More time for commercial availability.

GAPS: Needs for more evaluation using a broad collection of field samples, including serum samples and tissue samples from domestic pigs, wildboars and African wild suids infected with current circulating strains in Africa, and Caucasus and Russia.

Cost of developing new or improved diagnostics and their validation

Medium at Laboratory.

GAP: Support of programmes for sampling in Africa regions, Caucasus and Russia through collaboration with the affected countries and international organisations.

Research requirements for new or improved diagnostics

The serological recognition of carrier pigs has been vital for the success of eradication programmes.

GAPS:

  • More studies regarding the evaluation of ASF carrier status of surviving pigs and African wild Suids.
  • Characterization of ASFV isolates in reservoirs of Africa.
  • Genotyping without need of sequencing.
  • Determine the potential carrier status of animals infected with viral isolates in the Caucasus and the changes in virulence of the ASFV.

Technology to determine virus freedom in animals

New developments for vaccines

Requirements for vaccines development / main characteristics for improved vaccines

  • Identify candidate vaccines or components of the genome which should be effective against the mild and acute variants of ASF. Identify candidate vaccines or recombinant DNA based on analysis of the ASFV genome. Production of a molecularly-attenuated ASFV vaccine offers a challenging research project.
  • Conventional strategies for a vaccine have not been useful to date.
  • New strategies should be attempted.

GAP: 

  • Conventional strategies for a vaccine have not been useful to date.
  • New strategies should be attempted. 

Time to develop new or improved vaccines

10 years.

Cost of developing new or improved vaccines and their validation

High.

Research requirements for new or improved vaccines

  • Develop better understanding of the immune response to infection and the humoral and cellular basis for the lifelong immunity post infection. Identification of target proteins or genes.
  • Understanding of the host-pathogen interactions and whether immunity is humoral or cell mediated.
  • Assessment whether antibodies alone can passively protect pigs against ASF virus, has demonstrated not complete protection .There is not protection induced by passively acquired antibodies.

New developments for pharmaceuticals

Requirements for pharmaceuticals development

None at present.

Time to develop new or improved pharmaceuticals

Not applicable.

Cost of developing new or improved pharmaceuticals and their validation

Not applicable.

Research requirements for new or improved pharmaceuticals

None at present.

Disease details

Description and characteristics.

Pathogen

ASF (ASFV) is a complex large icosahedral enveloped DNA virus that exhibits many features common to both Iridovirus and Poxvirus families. This virus is currently classified as the only member of the family Asfarviridae. DNA structure is based on two variable ends and a conserved central region of about 125 kbp.The left and right variable ends of the genome encodes five multigene families (MGF). MGF are involved in the variability of the genome size within isolates, due to deletions and insertions of copies within MGF genes. In addition some MGF are involved in determining virulence and tick host-range.

GAPS:

  • Identification and role of viral genes interfering with host gene transcription.
  • Persistence mechanisms of the virus in the host.
  • The role of the MGF in the generation of antigenic variabilility and evasion of the immune system.
  • Role of ASFV proteins and induced proteins for an effective and protective immune mechanism in surviving infected animals, after challenge with homologous isolate.

Variability of the disease

Suids, wild and domestic, are the natural host of ASFV. Several species of soft ticks have been shown to be ASFV reservoirs and vectors.

ASFV don’t induce neutralising antibodies and this is why non serotype classification can be performed. ASFV genotyping based on the partial nucleotide genome sequence of the B646L gene, encoding the p72 protein allow to differentiate up to 22 distinct genotypes. The complete genome sequence of the E183L gene, encoding the p54 protein might be used also for subtyping. Enhanced discrimination between isolates can be obtained through the analysis of the central variable region (CVR) within B602L gene by characterization of the tandem repeats sequences (TRS). Different isolates belonging the same ASFV genotype vary in their ability to cause disease with some causing severe acute disease and high mortality while others exhibits subacute and chronic forms resulting in seroconversion.

GAP: Biological and molecular characterization of current circulating isolates belonging to different genotypes in Africa.

Stability of the agent/pathogen in the environment

T°: Highly resistant to low temperatures. Heat inactivated by 56°C/70 min; 60°C/30 min

pH: Inactivated by pH <3.9 or >11.5 in serum-free medium. Serum increases the resistance of the virus, e.g. at pH 13.4 - resistance lasts up to 21 hours without serum, and 7 days with serum

Chemicals: Susceptible to ether and chloroform.

Disinfectants: Inactivated by 8/1,000 sodium hydroxide (30 min), hypochlorites - 2.3% chlorine (30 min), 3/1,000 formalin (30 min), 3% ortho-phenylphenol (30 min) and iodine compounds. For animal housing and equipment, soaps and detergents, oxidising agents and alkalis are recommended.

Soaps, detergents and Alkalis are useful to disinfect machinery, clothing, and vehicles, human housing etc and also Vircon is also recommended to be employed in aircraft.

The procedure to be employed in feed, effluents, and manure, include bury or burn, or in the latter also by Acids and Alkalis.

Insecticides (organophosphates and synthetic pyrethroids) for tick eradication,

Survival: Remains viable for long periods in blood, faeces and tissues. Can multiply in vectors.

Species involved

Animal infected/carrier/disease

Swine are the only animal specie naturally infected by ASFV. The disease occurs through complex transmission cycles involving domestic pigs, wild boars, warthogs and bush pigs (African wild pigs).

Domestic pigs, wild boars and feral/American pigs are susceptible to ASFV infection showing a range of clinical signs and mortality rates. ASFV usually induces an asymptomatic infection in wild African pigs.

GAPS:

  • Assessment of the carrier status/resistant in domestic African pigs. 
  • Geographical distribution of wild boar.

Human infected/disease

None.

Vector cyclical/non-cyclical

Soft ticks (Ornithodoros spp), including O. moubata and O. erraticus also act as reservoirs and vectors for virus transmission. Transovarial, and sexual transmission can occur. In Africa, ASFV is thought to cycle between newborn warthogs and the soft ticks (Ornithodoros moubata) that live in their burrows. Individual ticks can apparently remain infected for life, and infected soft tick colonies can maintain this virus for years. All the Ornithodoros spp experimentally infected until now were susceptible to ASFV infection.

GAP: Geographical distribution in Europe and worldwide.

Reservoir (animal, environmental)

Wild African pigs, most importantly warthogs (Phacochoerus aethiopicus), bush pigs (Potamochoerus porcus) and giant forest hogs (Hylochoerus meinertzhageni) are also infected but usually do not exhibit clinical signs, acting as reservoir hosts in Africa usually showing an asymptomatic infection. These species of wild pigs act as reservoir hosts of ASFV in Africa. Soft ticks of the Ornithodoros genus have been shown to be both reservoirs and transmission vectors of ASFV (ASFV).

GAPS: Host-virus interaction in wild African pigs, determining asymptomatic infection.

Description of infection & disease in natural hosts

Transmissibility

Direct and indirect contact between infected and susceptible pigs/wild boar and wild African pigs (warhogs).

GAP: Studies on Neighbourhood transmission in densely population areas.

Pathogenic life cycle stages

Survivors of infection are virus carriers for life.

Signs/Morbidity

ASF viruses produce a range of syndromes varying from peracute, acute to chronic disease and apparently healthy virus carriers.

GAPS:

  • Host factors determining the clinical outcome of infection.
  • Follow up potential carrier status in the Caucasus and potential changes in virulence characteristics of the circulating isolates.

Incubation period

Incubation period is 3-15 days.

Mortality

Depending on the ASFV isolate virulence.

  • Acute form (highly virulent virus) -100%.
  • Subacute form (moderately virulent virus) 30-80% varies.
  • Chronic form –low mortality.

Shedding kinetic patterns

Unknown.

GAP: Shedding kinetic patterns.

Mechanism of pathogenicity

ASF is generally spread via oral and nasal routes, but also by tick bite, cutaneous scarification, and intramuscular, subcutaneous, intraperitoneal or intravenous injection. The incubation period varies widely (4-19 days), depending on the ASFV isolate and the route of exposure.
By oral route, monocytes and macrophages of the tonsils and mandibular lymph nodes are the first involved. From these sites, the virus spreads through the blood and/or lymphatic system to the main sites of secondary replication – i.e., lymph nodes, bone marrow, spleen, lung, liver, and kidney. Viremia usually begins 4-8 days post infection and persists for weeks or months. ASFV is associated with red blood cell membranes causing hemadsorption.

GAP: Pathogenesis mechanism of infection by ASFV of different virulence are not well understood.

 

Zoonotic potential

Reported incidence in humans

ASFV has never been shown to infect humans and is not considered to be a zoonotic pathogen.

Estimated level of under-reporting in humans

None.

Risk of occurence in humans, populations at risk, specific risk factors

None.

Symptoms described in humans

None.

Likelihood of spread in humans

None.

Impact on animal welfare and biodiversity

Both disease and prevention/control measures related

ASF outbreaks have an impact both due to the severity of the disease and with the introduction of control measures especially movement controls.

Endangered wild species affected or not (estimation for Europe / worldwide)

European species of wild pigs are affected but this is not the case for African wild pigs.

Slaughter necessity according to EU rules or other regions

Slaughter of infected and in contact pigs.

Geographical distribution and spread

Current occurence/distribution

African swine fever was first recorded in Kenya in 1921 and is present as endemic in most sub-Saharan African countries. It spread to southern Europe in 1957 (genotype I) affecting different countries in Europe and central and south America. In Europe, ASF is still endemic in Sardinia (Italy) and since 2007, it has been notified in the Caucasus region and Russia Federation (genotype II, associated to those circulating in Eastern- southern African regions). The events have proved that the threat of ASF spreading to other regions remains and it is potentially devastating to the global pig industry.

Source of information: www.oie.int and EU: Animal disease notification system (ADNS)

GAPS: Education, awareness and preparedness of veterinary staff and producers.

Epizootic/endemic- if epidemic frequency of outbreaks

Become endemic mainly in developing countries, due to presence of complex transmission cycles which could involve a sylvatic cycle, a domestic cycle and a pig-tick cycle.
Greatly influenced by presence – and subsequent infection - of wild boar and vectors (wild African pigs and soft ticks acting as reservoirs).
GAPS:
  • The role of wildboar as reservoir in Caucasus region and Russia Federation.
  • The role of soft ticks as reservoirs.
  • Vectorial capacity in Caucasus and bitting habits.
  • Evolution of the circulating strains in Europe and Africa, from the molecular and biological point of view, and what are the mechanism involve in virus maintenance.

Seasonal cycle (seasonality)

None.

Speed of spatial spread during an outbreak

Can be high mainly due to transport movements, and pig density.

GAP: The role of wild boars in spreading the disease under different conditions.

Transboundary potential of the disease

Potentially high and wide spreading, dependant on the movement of infected pigs/wild boars/ African wild pigs or infected meat or other pig products, and illegal movements.

Seasonal cycle linked to climate

No.

Distribution of disease or vector linked to climate

Not known.

Outbreaks linked to extreme weather

No.

Sensitivity of disease or vectors to the effects of climate change (environmental changes/land use)

Not known.

Route of Transmission

Usual mode of transmission (introduction, means of spread)

Direct transmission: contact between sick (domestic and wildboar) and healthy animals; contact with asymptomatic infected African wild reservoirs (carriers) and soft ticks

Indirect transmission:

  • feeding with garbage containing infected meat
  • fomites: premises, vehicles, implements, clothes, …

Occasional mode of transmission

Ornithodoros ticks, where present, can act as transmission vector of the ASF virus.

Conditions that favour spread

The virus can survive outside the pig for a long time, so the movement of contaminated vehicles, clothing, footwear and equipment can also spread disease.

  • Clinical diagnosis confused with other diseases such as CSF. It might delay diagnosis
  • Density of wild boar population.
  • Presence of wild African pigs and soft ticks.

GAP: The role of reservoirs in the transmission of the disease under different conditions.

Detection and Immune response to infection

Mechanism of host response

Pigs often die before the development of a humoral response when infected with a virulent strain. Pigs which do not die will mount an antibody response and have significant levels of ASF specific cytotoxic T lymphocytes. Pigs will demonstrate a solid immunity to challenge from homologous strains but not heterologous strains. However there is an absence of neutralizing antibodies against ASFV.

The ASF V replicates in porcine macrophages.

The essential effectors immune mechanisms involved in protection against ASF are poorly understood. All attempts to develop an effective vaccine have been unsuccessful to date.

GAPS:

  • The role of MGF and its manipulation to induce a protective immune response.
  • Identification and role of viral genes interfering with host gene host defences and immune response .
  • Deeper characterization of viral interactions with pig macrophages and with the host (domestic pigs) , in ASFV infection with isolates exhibiting different virulence, and well characterised at genome level, may open new insights for the manipulation of pig immune responses, towards the stimulation of protective immune response.
  • Deeper effectors immune mechanisms characterization, involved in protection in surviving pigs.
  • Characterization of the immune response in wild African suids.

Immunological basis of diagnosis

Detection of antibodies and evidence of the virus genome or virus antigen. ASFV infection produce a long-term viremia at early time of infection. Specific IgG antibodies is detectable in blood from the first week and for a long period of time, months even year, in the surviving pigs. The early appearance and subsequent persistence of antibodies is the reason they are so useful in studying subacute and chronic forms of the disease. For the same reason, they play an important role in testing strategies implemented as part of eradication programmes.

Main means of prevention, detection and control

Sanitary measures

Control of live animals and swine productos imports, control of waste food. Movement controls can all be successful. Quarantine. Once established in an area tick control becomes important using acaricides.

  • Strict sanitary measures on infected farms, stamping out of animals, cleansing, disinfection, sentinels, serological control of sentinels after a month.
  • Identification of carrier pigs. Stamping out.

GAP: New control strategies and eradication models depending on the epidemiological situation, taking into account the complex transmission cycles, involving domestic pigs and the presence of wild boar and/or soft ticks and /or wild African pigs.

Mechanical and biological control

  • Avoid contact between pigs, wild boar and soft tick vectors, including warhogs in Africa - i.e. prevent pigs from wandering.
  • Performing a good tracing sources of infection and sources of spreading.

Diagnostic tools

Since not vaccine is available, ASF diagnosis by virus detection and serological tests are critical for disease containment.

Described in Diagnostic Manual 2003/422/EC and in the OIE Manual of Diagnostic Tests and Vaccines for Terrestrial animals, 2008:

Virus detection and isolation :

  • Virus isolation/Haemadsorption test(CPE/HAD) (HAD).
  • PCR techniques: Real-time and Conventional gel based PCR,
  • Direct Immunofluorescence (DIF). Low sensitivity, in case of specific antibody presence.
  • Ag-ELISA INGENASA K2 INGEZIM PPA DAS 11.PPA.K2, commercial kit (Ag-ELISA). Low sensitivity. Not recommended for screening of individual animals.

ASF antibody detection:

  • OIE indirect ELISA (OIE-ELISA) described in the OIE Manual of diagnosis (OIE, 2008).
  • OIE Immunoblotting (OIE-IB) described in the OIE Manual of diagnosis (OIE, 2008)
  • ELISA commercial kit INGENASA K3 Ingezim PPA Compac (11.PPA k3).
  • Indirect Immunofluorescence IIF. described in the OIE Manual of diagnosis (OIE, 2008)
  • Immunoperoxidase technique (IPT) on BA71V-VERO infected cells (not included in the OIE Manual. Reference technique at the ASF CRL already validated).

GAPS:

  • Assessment of diagnostic techniques up date in relation to the new circulating isolates and taking into account all to all epidemiological situations.
  • Penside tests for onsite diagnosis.

Vaccines

None available at present.

GAPS:

  • More research based on virus-host interaction and immunity against infection, in a view of a vaccine ,
  • Research based on new strategies, i.e: evaluation of genome integration as a persistence factor, etc.
  • New strategies to develop an effective vaccine using non-conventional approaches.

Therapeutics

No effective treatment.

GAP: Potential of antivirals. It may be of interest in ASF control.

Biosecurity measures effective as a preventive measure

Rapid slaughtering of all pigs and proper disposal of cadavers and litter is essential. Thorough cleaning and disinfection. Movement controls.

Border/trade/movement control sufficient for control

  • Careful import policy for animals and animal products.
  • Proper disposal of waste food from aircraft or ships coming from infected countries.

GAP: Not always fully enforced.

Prevention tools

Efficient sterilisation of garbage.

GAP: Don´t use swill feeding is not fully enforced in certain countries.

Surveillance

In an outbreak surveillance of infected zone, and surrounding area is important. Pigs recovered from acute or chronic infections usually exhibit a viraemia for several weeks making the PCR test a very useful tool for the detection of ASFV in pigs infected with low or moderately virulent strains. In addition, Antibody detection techniques are very useful in detecting surviving infected animals.

Past experiences on success (and failures) of prevention, control, eradication in regions outside Europe

Recovered ASFV carrier pigs and persistently infected wild pigs constitute the biggest problems in controlling the disease. Eradication was successful in the Iberian Peninsula and in the Caribbean.

Some common failures have been identified:

  • Late detection.
  • Low/insufficient resources or political unstability.
  • Scavenging pig husbandry or free-roaming pigs.
  • Uncooked swill feed.
  • Presence of wild pigs and ticks as reservoirs.
  • Co-circulation of several isolates and or genotypes with different characteristics.
  • Failure to identify risk factors.

Invert in prevention is the best measure to avoid the significant socio-economical consequences of this disease.

GAPS:

  • To Develop of models taking into account the different scenarios, /specific epidemiological conditions, for best control options.
  • To develop Risk mapping to support a targeted surveillance/control programme.

Costs of above measures

Cost can be are high. Outbreaks in Europe were controlled by animal quarantine and slaughter, frequently at a very high cost.

Disease information from the OIE

Disease notifiable to the OIE

Yes.

OIE disease card available

http://www.oie.int/fileadmin/Home/eng/Media_Center/docs/pdf/Disease_cards/ASF-EN.pdf

OIE Terrestrial Animal Health Code (reference)

http://www.oie.int/index.php?id=169&L=0&htmfile=chapitre_1.15.1.htm

OIE Terrestrial Manual (reference)

http://www.oie.int/fileadmin/Home/eng/Health_standards/tahm/2.08.01_ASF.pdf

Socio-economic impact

Zoonosis: Impact on affected individuals and/or aggregated DALY figures

None.

Zoonosis: cost of treatment and control of the disease in humans

None.

Direct impact (a) on production

Variable depending on the strains involved. With 100% mortality can have a very high cost. This disease produces huge economic and social loses in many African countries, and impairs the development of the porcine industry.

Direct impact (b) cost of private and public control measures

Disease outbreaks have occurred in Europe, South America, and the Caribbean; the cost of eradication has been significant. During outbreaks in Malta and the Dominican Re-public, the swine herds of these countries were completely depopulated. In Spain and Portugal, ASFV became endemic in the 1960s and complete eradication took more than 30 years.

Indirect impact

Main indirect impact is on the constraints on livestock production and the trade in pigs and their products. Loss of export markets.

Trade implications

Impact on international trade/exports from the EU due to existing regulations

Controls on the movement, of pigs and products from infected countries. Likely ban on imports from affected countries. Quarantine measures.

Impact on EU intra-community trade due to existing EU regulations

Movement controls on live pigs and their products from infected areas.

Impact on national trade due to existing regulations

Restrictions and controls on internal movements form the protection and surveillance zones.

Main perceived obstacles for effective prevention and control

Lack of vaccines, carrier recovered pigs, reservoirs in ticks and wild pigs in Africa.

  • Improvement of sanitary infrastructures at animal holdings and Biosecurity in some countries.
  • Individual identification of every animal.
  • Census up date, in some countries.

GAPS:

  • Lack of awareness by farmers, and veterinary staff.
  • Improvement of control strategie
  • Improvement of control measures by means of:
  • improvement of sanitary infrastructures at animal holdings and Biosecurity in some countries. .
  • Individual identification of every animal. Census up date in some countries.
  • epidemiological surveys.
  • promoting associations.

Main perceived facilitators for effective prevention and control

Appropriate vaccines, ability to identify carriers, control of ticks.

  • Improvement of sanitary infrastructures at animal holdings and Biosecurity in some countries. .
  • Individual identification of every animal.
  • Census up date, in some countries.

Risk

Changes in production practices and increased globalization have in-creased the risk of African swine fever being introduced into free areas. The main risk of ASF introduction into Europe is via infected pig meat or pig meat products, for example illegally imported pig meat or bush meat from infected countries or legally imported meat from areas with undetected infection.

GAPS:

  • Control movements.
  • Improve awareness of field staff, veterinary and producers.
  • Biosecurity
  • Type of holdings.: free ranging of back-yards.
  • The role of soft ticks in the potential ASF transmission and their distribution in European countries requires further investigation.

Conclusion

ASF has the potential to enter free countries if sanitary and border controls are ineffective. The development of effective vaccines for contingency use in Europe and for routine use in endemic countries would be advantageous.

Sources of information

Name of expert group leader

Jose-Manuel Sanchez-Vizcaino - Director del Laboratorio de Referencia de la OIE, Universidad Complutense de Madrid

Name of reviewers

Project Management Board.

Date of preliminary approval

22nd January 2011.

Date of final approval

26th April 2011.